The study did not receive ethics approval, or participant consent, to place a study dataset in the public domain. The data used in this study can be made accessible to qualified researchers upon reasonable request pursuant to any restrictions required to ensure the privacy of human subjects involved. Access to data will be subject to a data sharing agreement approved by University of Aberdeen. Researchers interested in accessing USEFUL data should send their request to the study\'s PI, Professor Philip Hannaford (<p.hannaford@abdn.ac.uk>).

Introduction {#sec006}
============

Although there has been important progress in recent years, the United Kingdom (UK) continues to have poorer cancer survival rates than similarly developed countries in Europe and beyond \[[@pone.0228033.ref001]\]. Current national cancer strategies in England \[[@pone.0228033.ref002]\] and Scotland \[[@pone.0228033.ref003]\] include cancer awareness campaigns as part of a range of actions aimed at closing this survival gap. Cancer awareness campaigns seek to increase the public's awareness of the link between certain signs and symptoms and cancer, and encourage their prompt presentation to healthcare services. The need for such initiatives is indicated partly by evidence that many people in the UK rarely consider their symptoms to be a possible indicator of cancer \[[@pone.0228033.ref004]\], even in high risk groups such as smokers \[[@pone.0228033.ref005]--[@pone.0228033.ref008]\]. Indeed there may be a general lack of awareness of cancer symptoms among the UK population \[[@pone.0228033.ref009]--[@pone.0228033.ref012]\].

Effective targeting of cancer awareness campaigns requires contemporaneous information about the prevalence and distribution of cancer-related symptoms within the general population, and associated patterns of help-seeking behaviour- in the UK particularly general practitioner (GP) contact. Studies from Denmark show that cancer-related symptoms are common in the general population. A cross-sectional study conducted in 2007 of 13,777 adults older than 19 years and living in Funen, Denmark, reported that 15% of participants had at least one of four common cancer red flag symptoms (also known as alarm symptoms) in the preceding 12 months \[[@pone.0228033.ref013]\]. A larger, predominantly internet-based survey undertaken in 2012 of 49,706 adults older than 19 years and residing across Denmark, found that 90% experienced in the preceding four weeks at least one of 44 symptoms, including red flag symptoms of lung, gastro-intestinal, gynaecological and urogenital cancer; mean number of any symptom 5.4 (Standard Deviation, SD not given) \[[@pone.0228033.ref014]\].

In the UK, a pooled analysis of two primary-care based surveys involving 3,756 adults older than 49 years found that 46% of respondents had experienced at least one of 10 cancer red flag symptoms in the previous three months; mean number of symptoms 1.73 (SD 1.17) \[[@pone.0228033.ref015]\]. Overall, a third of people with symptoms had not contacted their GP about them, with the proportion seeking help varying by symptom experienced and characteristics of respondents. These findings suggest important opportunities for the targeting of cancer awareness campaigns. Key limitations of these UK studies, however, include the use of symptoms from the Cancer Awareness Measure \[[@pone.0228033.ref016]\] rather than those specific to cancer site (e.g. rectal bleeding for colorectal cancer or lump in breast for breast cancer), the small sample size and the relatively small number of respondent characteristics assessed. Another UK general population study of the prevalence of 25 physical and psychological symptoms in working-age adults provided limited information about cancer-related symptoms \[[@pone.0228033.ref017], [@pone.0228033.ref018]\].

The Understanding Symptom Experiences Fully (USEFUL) study aims to improve understanding of the prevalence, patterning and response to symptoms associated with breast, colorectal, lung and upper gastrointestinal cancer in older adults living in the UK general population. We report here its findings in relation to the experienced prevalence of symptoms possibly indicative of these four cancers, the characteristics of people experiencing those symptoms, the levels of self-reported GP help-seeking and the characteristics of those taking this action.

Methods {#sec007}
=======

Ethics statement {#sec008}
----------------

National Research Ethics Service Committee East Midlands- Derby (REC reference 14/EM/1124. IRAS Project ID 160441) confirmed its favourable ethical opinion of the study, and each relevant National Health Service authority gave Research and Development management approval before the survey began. All participants received written information about the study; participants were deemed to have been given consent to participate by returning a completed questionnaire.

Study design {#sec009}
------------

The USEFUL study was underpinned by theoretical models developed to understand response to symptoms. The Model of Pathways to Treatment \[[@pone.0228033.ref019]\] provided a framework for distinguishing key events in the cancer diagnostic pathway. A framework integrating understanding from three process models of response to symptoms, the Commonsense Self-Regulation Model (CSM) \[[@pone.0228033.ref020]\], the Illness Action Model \[[@pone.0228033.ref021]\] and the Network Episode Model \[[@pone.0228033.ref022]\] guided investigation of the way in which symptoms and responses to them are interpreted and evaluated by people experiencing them.

The first phase of the USEFUL study involved surveying a large community-based sample of adults aged 50 years or more. This age group was chosen because of its higher risk of cancer and its frequent focus for cancer prevention interventions such as screening programmes or cancer awareness campaigns.

Questionnaire development {#sec010}
-------------------------

A questionnaire for self-completion was developed to explore symptoms possibly indicative of breast, colorectal, lung and upper gastrointestinal cancer. Breast, colorectal and lung cancer were chosen as these are amongst the four most common cancers in the UK; all usually present symptomatically. Upper gastrointestinal cancer was included because it is a relatively common cancer often associated with non-specific symptoms and long diagnostic intervals. All of the chosen cancers have been the subject of cancer awareness campaigns conducted in the UK. The choice of symptoms for inclusion in the questionnaire was guided by a review of academic literature and current clinical guidelines, and discussion with academic and clinical colleagues. The wording of each selected symptom was guided by academic literature, academic clinicians and, crucially, lay members of the University of Aberdeen College of Life Sciences and Medicine Patient Engagement Group, who provided key input into questionnaire format and wording, particularly whether the symptom descriptors captured lay understanding of each symptom. Five of the chosen symptoms included the word 'persistent' in an attempt to differentiate between symptoms that clinicians or campaigns may consider more serious and more likely to be indicative of cancer rather than a self-limiting illness. The final questionnaire included two symptoms possibly indicative of breast cancer, four of colorectal cancer, seven of lung cancer and five of upper gastrointestinal cancer ([Table 1](#pone.0228033.t001){ref-type="table"}). Six symptoms (*difficulty swallowing*, *unexplained weight loss*, *coughing up blood*, *blood in stool or rectal bleeding*, *vomiting up blood*, *lump in breast* were red flag symptoms (alarm or warning symptoms and/or signs that suggest a potentially serious underlying disease.) These red flag symptoms were based on those highlighted in cancer referral guidelines. The questionnaire also asked about three 'non-specific' symptoms possibly indicative of cancer at any site; and four more general, 'masking', symptoms less likely to be indicative of cancer (to help conceal the focus of the questionnaire). In a further attempt to avoid biasing responses we broke up the ordering of symptoms. The questionnaire was piloted in two general practices in England and Scotland, and subsequently modified slightly before the main mailing. [S1 File](#pone.0228033.s003){ref-type="supplementary-material"} details the full content of the questionnaire.

10.1371/journal.pone.0228033.t001

###### Symptom description and type included in the questionnaire, listed as presented in the questionnaire.
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  Headaches                                                                 Masking symptom
  ------------------------------------------------------------------------- ------------------------------------------
  Persistent indigestion/heartburn                                          Upper gastrointestinal cancer associated
  Difficulty swallowing [!!](#t001fn001){ref-type="table-fn"}               Upper gastrointestinal cancer associated
  Stomach or abdominal pain                                                 Upper gastrointestinal cancer associated
  Chest pain                                                                Lung cancer associated
  Hoarseness                                                                Lung cancer associated
  Loss of appetite                                                          Non-specific cancer associated
  Unexplained weight loss [!!](#t001fn001){ref-type="table-fn"}             Non-specific cancer associated
  Persistent cough                                                          Lung cancer associated
  Change in ongoing cough                                                   Lung cancer associated
  Persistent diarrhoea                                                      Colorectal cancer associated
  Persistent constipation                                                   Colorectal cancer associated
  Coughing up phlegm                                                        Lung cancer associated
  Coughing up blood [!!](#t001fn001){ref-type="table-fn"}                   Lung cancer associated
  Shortness of breath                                                       Lung cancer associated
  Wheezy chest                                                              Masking symptom
  Change in bladder habits                                                  Masking symptom
  Change in bowel habits                                                    Colorectal cancer associated
  Blood in stool or rectal bleeding [!!](#t001fn001){ref-type="table-fn"}   Colorectal cancer associated
  Back or joint pain                                                        Masking symptom
  Persistent vomiting                                                       Upper gastrointestinal cancer associated
  Vomiting up blood [!!](#t001fn001){ref-type="table-fn"}                   Upper gastrointestinal cancer associated
  Lump in breast [!!](#t001fn001){ref-type="table-fn"}                      Breast cancer associated
  Breast change other than lump                                             Breast cancer associated
  Tired all the time                                                        Non-specific cancer associated

!! = red flag cancer symptom

Data collection {#sec011}
---------------

Between May 2015 and January 2016, invitation letters were sent on behalf of 21 general practices (10 in Staffordshire, England and 11 across Scotland), to 50,000 adults aged 50 years or more. The sample size was based on a desire for reasonable precision for the annual prevalence of common symptoms (e.g. *a priori* point estimate for *lump in breast* of 3.3%, 99% confidence interval 3.0 to 3.6, assuming a response rate of 40%).

Practices were identified by two primary care research networks asked to recruit practices with different levels of rurality and deprivation. Coordinators from the networks ran searches to identify eligible patients and applied pre-specified exclusion criteria (dementia, learning disabilities, living in a nursing home or receiving palliative care). GPs in each practice were then asked to check the lists for any other patients they wished to exclude. The reason for, and number of, such exclusions was not collected. In practices with fewer than 2,500 patients aged 50+ years, all patients were identified and screened. In larger practices, a random sample of those aged 50+ years was taken to achieve the overall required sample size.

Eligible individuals remaining after exclusions were sent a study information leaflet and invitation to complete an online questionnaire. The invitees were told that the study's purpose was to enquire about symptoms experienced, their effects, participants' thoughts about the symptoms, and actions taken. Cancer was not mentioned, to avoid anxiety and minimise the risk of biasing responses. Non-respondents received reminders three and six weeks after the initial invitation letter. Reminders included a printed questionnaire to enable completion by post if preferred. Patients were able to opt-out by a study telephone number, e-mail or return of a blank questionnaire.

Data management {#sec012}
---------------

In order to maintain invitee confidentiality, study packs were dispatched by the University of Aberdeen Data Management Team in Scotland and by the West Midlands Clinical Research Network in England. Questionnaires (identified by participant ID only) were returned to the research team at the Centre for Academic Primary Care, University of Aberdeen. The Data Management Team had access to the full postcode of respondents, to assign rurality and deprivation score. Postcode data were removed from the main dataset before it was forwarded to the research team for analysis. For participants from England we used the English higher level geographies Rural-Urban Classification 2011 \[[@pone.0228033.ref023]\] and Index of Multiple Deprivation (IMD) for England 2015 \[[@pone.0228033.ref024]\], and for those from Scotland, the Scottish Government 6-fold Urban Rural Classification 2013/2014 \[[@pone.0228033.ref025]\] and Scottish Index of Multiple Deprivation (SIMD) 2012 \[[@pone.0228033.ref026]\].

Data analysis {#sec013}
-------------

After data cleaning, differences between groups with categorical data was assessed using the Chi-squared test. The proportion of individuals overall and in different subgroups reporting individual or combinations of symptoms possibly indicative of different cancers was calculated using SPSS Statistics version 24 \[[@pone.0228033.ref027]\], and Allto consulting software \[[@pone.0228033.ref028]\] for surrounding 99% confidence intervals. The chance of reporting symptoms possibly indicative of cancer, and associated GP help-seeking, in different population subgroups was estimated using binary logistic regression in SPSS, to calculate unadjusted and adjusted odds ratios, and their surrounding 99% confidence intervals. We estimated 99% confidence intervals because of the large number of proportions and odds ratios calculated. Variables chosen *a priori* for inclusion in the adjusted model were based on previous research \[[@pone.0228033.ref017], [@pone.0228033.ref018]\]: gender, age, marital status, social support, education, employment, household income, smoking, rurality and history of any of the medical conditions specified in the questionnaire. All of the variables were entered simultaneously into the model To enable the entire dataset to be used in the adjustments, the six Scottish levels and three English levels of each country's rural-urban classification were combined into a single nine-level categorical variable, with Scottish large urban areas as the referent group. We used the area-based deprivation variables to examine whether response rates were related to this characteristic. We did not, however, use them in the adjusted models as other, individual-based, measures of socioeconomic status were available for respondents. It should be noted that the denominator for proportions sometimes changed because of missing values or inconsistent responses that could not be reconciled. In the analyses looking at GP help-seeking, symptomatic people with information missing about contact with their GP were assumed not to have seen their family doctor, and so were combined with those responding no to questions about this action.

Results {#sec014}
=======

Response {#sec015}
--------

After three mailings, 16,778 completed questionnaires were returned (corrected response rate after removing 403 deaths or de-registrations and 565 undelivered questionnaires 34.2%; range between practices 18.1% to 45.7%). Roughly a third of all questionnaires were completed on-line (5182, 30.9%), with a higher proportion from respondents in Scotland than England (35.1% vs 26.2%; x^2^ = 155.4, p\<0.001). In both Scotland and England significantly higher response rates were achieved from women, those living in more rural areas and those in less deprived areas ([S1 Table](#pone.0228033.s001){ref-type="supplementary-material"}). The response rate in England increased significantly with age from 50--54 to 70--74 years before declining in older age groups; there were no significant age differences in Scotland.

Characteristics of respondents {#sec016}
------------------------------

More than half of all respondents were female (53.8%), younger than 70 years (71.0%), married or living with a partner (74.4%), had high social support (58.5%), had a professional, degree or postgraduate qualification (50.6%), were retired (53.4%), had never smoked (54.0%) and lived in an urban area (England 70.8%, Scotland 52.7%), [Table 2](#pone.0228033.t002){ref-type="table"}. Most participants indicated a history of having been diagnosed with at least one of the conditions specified in the questionnaire (78.9%). The most common conditions were high blood pressure (32.8% of all respondents), arthritis/rheumatic disorder (23.5%) and stomach/digestive disorders (18.4%). Roughly a tenth of respondents (10.6%) reported having ever been diagnosed with cancer. Nearly all respondents reported being in good (35.0%), very good (36.1%) or excellent (11.4%) health.

10.1371/journal.pone.0228033.t002

###### Selected socio-demographic characteristics of respondents in the study.
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  Demographic group                                                           Sub-group                       N      \%
  --------------------------------------------------------------------------- ------------------------------- ------ ------
  **Sex**                                                                     Male                            7745   46.2
  Female                                                                      9033                            53.8   
  **Age group**                                                               50--59                          5564   33.1
  60--69                                                                      6350                            37.9   
  70--79                                                                      3712                            22.1   
  80+                                                                         1152                            6.9    
  **Marital status**                                                          Single                          1114   6.8
  Married/living together                                                     12272                           74.4   
  No longer married                                                           3100                            18.8   
  **Social support**                                                          Low                             910    5.8
  Medium                                                                      5572                            35.4   
  High                                                                        9263                            58.8   
  **Educational status**                                                      No educational qualifications   2050   12.6
  Secondary school or equivalent                                              5356                            32.8   
  College/vocational courses and other                                        660                             4.0    
  Professional qualification                                                  4250                            26.1   
  Degree or postgraduate qualification                                        3996                            24.5   
  **Employment status**                                                       Working full-time               3870   23.5
  Working part-time                                                           1598                            9.7    
  Self-employed                                                               1226                            7.5    
  Retired                                                                     8780                            53.4   
  Unable to work due to illness/disability                                    423                             2.6    
  Others not in paid employment                                               552                             3.4    
  **Household income**                                                        \< £15,000                      3561   24.0
  £15,000--29,999                                                             4523                            30.5   
  £30,000--49,999                                                             3650                            24.6   
  \>£50,0000                                                                  3106                            20.9   
  **Smoking status**                                                          Never smoked                    8872   54.0
  Ex-smoker                                                                   6095                            37.1   
  Current smoker                                                              1471                            8.9    
  **Urban Rural Classification Scotland**                                     Large urban areas               3234   36.5
  Other urban areas                                                           1434                            16.2   
  Accessible small towns                                                      640                             7.2    
  Remote small towns                                                          1569                            17.7   
  Accessible rural                                                            959                             10.8   
  Remote rural                                                                1013                            11.4   
  **Rural Urban Classification England**                                      Urban with city and town        2367   30.1
  Urban with significant rural                                                3201                            40.7   
  Largely rural                                                               2293                            29.2   
  **Diagnosis of specified condition [†](#t002fn001){ref-type="table-fn"}**   No                              3534   21.1
  Yes                                                                         13244                           78.9   

**†** ever been diagnosed with asthma, cancer, epilepsy, chronic bronchitis/COPD, other chest disorder, heart disorder, stroke, diabetes, high blood pressure, liver disorder, arthritis/rheumatic disorder, mental health disorder, thyroid disorder, stomach/digestive disorder, other condition (to be specified).

Most (76.0%) respondents said that we could review their medical records, 39.4% agreed to a telephone interview and 66.1% agreed to being contacted about future studies.

Total number of symptoms experienced {#sec017}
------------------------------------

Over two thirds (69.4%) of all respondents had experienced at least one of the 25 symptoms in the last month; 26.5% had 3 or more symptoms ([Table 3](#pone.0228033.t003){ref-type="table"}). These figures were almost identical when participants reporting a history of cancer were excluded (69.1% and 26.1% respectively). Since this was the case, and since people diagnosed with one cancer would still be targets for cancer awareness campaigns for other cancers, we have presented results based on replies from all respondents. Nearly half (45.8%) of all respondents had at least one symptom possibly indicative of the four cancers in the last month; 13.3% had 3 or more such symptoms, mean number 1.01 (SD 1.57) ([Table 3](#pone.0228033.t003){ref-type="table"}). Symptom prevalence was slightly higher when the time frame of last year was used; 80.0% of all respondents experienced at least one of the 25 symptoms and 58.5% at least one symptom possibly indicative of the four cancers (mean number 1.51, SD 1.96).

10.1371/journal.pone.0228033.t003

###### Number of symptoms experienced in the last month and year by the respondents.
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                               All respondents (N = 16778)   Respondents without a diagnosis of cancer (n = 15001)                                                    
  ---------------------------- ----------------------------- ------------------------------------------------------- ------------- ------------- ------ ------ ------ ------
  **Symptoms in last month**                                                                                                                                          
  0                            5142                          30.6                                                    9095          54.2          4641   30.9   8224   54.8
  1                            4282                          25.5                                                    3580          21.3          3858   25.7   3199   21.3
  2                            2918                          17.4                                                    1860          11.1          2598   17.3   1649   11.0
  3                            1774                          10.6                                                    994           5.9           1587   10.6   863    5.8
  4                            973                           5.8                                                     544           3.2           860    5.7    468    3.1
  5                            635                           3.8                                                     319           1.9           548    3.7    284    1.9
  \>5                          1054                          6.3                                                     386           2.3           909    6.1    314    2.1
  Mean (SD)                    1.82 (2.09)                   1.01 (1.57)                                             1.79 (2.06)   0.98 (1.53)                        
  **Symptoms in last year**                                                                                                                                           
  0                            3357                          20.0                                                    6968          41.5          3031   20.2   6319   42.1
  1                            3503                          20.9                                                    3715          22.1          3166   21.1   3334   22.2
  2                            3114                          18.6                                                    2365          14.1          2783   18.6   2093   14.0
  3                            2225                          13.3                                                    1448          8.6           1982   13.2   1284   8.6
  4                            1484                          8.8                                                     893           5.3           1332   8.9    780    5.2
  5--7                         2190                          13.1                                                    1092          6.5           1936   12.9   957    6.4
  8--10                        649                           3.9                                                     250           1.5           569    3.8    199    1.3
  \>10                         256                           1.5                                                     47            0.3           202    1.3    35     0.2
  Mean (SD)                    2.61 (2.55)                   1.51 (1.96)                                             2.58 (2.51)   1.47 (1.92)                        

SD = Standard Deviation

Individual symptoms experienced {#sec018}
-------------------------------

There was a wide range in the reported prevalence of individual symptoms possibly indicative of cancer; for example, in the last month between near zero (*vomiting up blood*) and 15.0% (*tired all the time*) ([Table 4](#pone.0228033.t004){ref-type="table"}). Red flag symptoms were at the lower end of the prevalence range. Even so, 7.4% of respondents reported experiencing at least one of the six red flag symptoms in the last month, and 12.7% in the last year.

10.1371/journal.pone.0228033.t004

###### Proportion of respondents having experienced symptoms possibly indicative of different cancers in the last month and year, and proportion of those with the symptoms who contacted their GP about it.
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                                                                            In last month                                                        In last year:                                                                                                                                              
  ------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Persistent indigestion/heartburn                                          1969 (11.7, 11.1--12.3)                                              330 (16.8, 14.6--19.0)                                                         2769(16.5, 15.8--17.2)                                                      1221 (44.1, 41.7--46.5)
  Difficulty swallowing [!!](#t004fn003){ref-type="table-fn"}               573 (3.4, 3.0--3.8)                                                  103 (18.0, 13.9--22.1)                                                         884 (5.3, 4.9--5.6)                                                         327 (37.0, 32.8--41.2)
  Stomach or abdominal pain                                                 1661 (9.9, 9.3--10.5)                                                427 (25.7, 22.9--28.5)                                                         2734 (16.3, 15.6--17.0)                                                     1322 (48.4, 45.9--50.9)
  Persistent vomiting                                                       36 (0.2, 0.1--0.3)                                                   18 (50.0, 28.5--71.5)                                                          95 (0.6, 0.5--0.8)                                                          57 (60.0, 47.1--73.0)
  Vomiting up blood [!!](#t004fn003){ref-type="table-fn"}                   3 (0.0, 0.0--0.0)                                                    0 (-)                                                                          12 (0.1, 0.0--0.2)                                                          7 (58.3, 21.6--95.0)
  ***At least one upper GI tract cancer symptom***                          ***3418 (20*.*4*, *19*.*6--21*.*2***)                                ***715 (20*.*9*, *19*.*1--22*.*7)*** [^◊^](#t004fn004){ref-type="table-fn"}    ***4929 (29*.*4*, *28*.*5--30*.*3)***                                       ***2464 (50*.*0*, *48*.*2--51*.*8)*** [^◊^](#t004fn004){ref-type="table-fn"}
  Chest pain                                                                908 (5.4, 5.0--5.9)                                                  283 (31.2, 27.2--35.2)                                                         1490 (8.9, 8.3--9.5)                                                        842 (56.5, 53.2--59.8)
  Hoarseness                                                                775 (4.6, 4.2--5.0)                                                  117 (15.1, 11.8--18.4)                                                         1319 (7.9, 7.4--8.4)                                                        378 (28.7, 25.5--31.9)
  Persistent cough                                                          1356 (8.1, 7.6--8.6)                                                 378 (27.9, 24.8--31.0)                                                         2189 (13.0, 12.3--13.7)                                                     1101 (50.3, 47.6--53.1)
  Change in ongoing cough                                                   188 (1.1, 0.9--1.3)                                                  62 (33.0, 24.2--41.8)                                                          298 (1.8, 1.5--2.1)                                                         145 (48.7, 41.2--56.2)
  Coughing up phlegm                                                        1481(8.8, 8.2--9.4)                                                  288 (19.4, 16.8--22.1)                                                         2241 (13.4, 12.7--14.1)                                                     850 (37.9, 35.3--40.5)
  Coughing up blood [!!](#t004fn003){ref-type="table-fn"}                   36 (0.2, 0.1--0.3)                                                   10 (27.8, 8.6--47.0)                                                           91 (0.5, 0.4--0.6)                                                          60 (65.9, 53.1--78.7)
  Shortness of breath                                                       1989 (11.9, 11.3--12.5)                                              562 (28.3, 25.7--30.9)                                                         2647 (15.8, 15.1--16.5)                                                     1419 (53.6, 51.1--56.1)
  ***At least one lung cancer symptom***                                    ***4194 (25*.*0*, 24.1--25.9)**                                      ***1024 (24*.*4*, *22*.*7--26*.*1)*** [^◊^](#t004fn004){ref-type="table-fn"}   ***5880 (35*.*0*, *34*.*1--36*.*0)***                                       ***3131 (53*.*2*, *50*.*9--55*.*5)*** [^◊^](#t004fn004){ref-type="table-fn"}
  Persistent diarrhoea                                                      499 (3.0, 2.7--3.3)                                                  115 (23.0, 18.2--27.9)                                                         729 (4.3, 3.9--4.7)                                                         343 (47.1, 42.3--51.9)
  Persistent constipation                                                   726 (4.3, 3.9--4.7)                                                  129 (17.8, 14.1--21.5)                                                         964 (5.7, 5.2--6.2)                                                         435 (45.1,41.0--49.2)
  Change in bowel habits                                                    837 (5.0, 4.6--5.4)                                                  235 (28.1, 24.1--32.1)                                                         1323 (7.9, 7.4--8.4)                                                        641 (48.5, 45.0--52.0)
  Blood in stool or rectal bleeding [!!](#t004fn003){ref-type="table-fn"}   487 (2.9, 2.6--3.2)                                                  94 (19.3, 14.7--23.9)                                                          872 (5.2, 4.8--5.6)                                                         399 (45.8, 41.5--51.2
  ***At least one colorectal cancer symptom***                              ***2013 (12*.*0*, 11.4--12.7)**                                      ***416 (20*.*7*, *18*.*4--23*.*0)*** [^◊^](#t004fn004){ref-type="table-fn"}    ***2897 (17*.*3*, *16*.*6--18*.*1)***                                       ***1404 (48*.*5*, *45*.*1--51*.*9)*** [^◊^](#t004fn004){ref-type="table-fn"}
  Lump in breast [!!](#t004fn003){ref-type="table-fn"}                      77 (0.5, 0.4--0.6)                                                   24 (31.2, 17.6--44.8)                                                          175 (1.0, 0.8--1.2)                                                         135 (77.1, 68.9--85.3)
  Breast change other than lump                                             110 (0.7, 0.5--0.9)                                                  42 (38.2, 26.3--50.1)                                                          208 (1.2, 1.0--1.4)                                                         132 (63.5, 54.9--72.1)
  ***At least one breast cancer symptom***                                  ***178 (1*.*1*, 0.9--1.3)** [^‡^](#t004fn005){ref-type="table-fn"}   ***63 (35*.*4*, *26*.*2--44*.*6)*** [^◊^](#t004fn004){ref-type="table-fn"}     ***355 (2*.*1*, *1*.*8--2*.*4)*** [^‡‡^](#t004fn006){ref-type="table-fn"}   ***259 (73*.*0*, *66*.*9--79*.*1)*** [^◊^](#t004fn004){ref-type="table-fn"}
  Loss of appetite                                                          478 (2.8, 2.5--3.1)                                                  100 (20.9, 16.1--25.7)                                                         883 (5.3, 4.9--5.8)                                                         276 (31.3, 27.3--35.3)
  Unexplained weight loss [!!](#t004fn003){ref-type="table-fn"}             158 (0.9, 0.7--1.1)                                                  63 (39.9, 29.9--49.9)                                                          341 (2.0, 1.7--2.3)                                                         189 (55.4, 48.5--62.3)
  Tired all the time                                                        2516 (15.0, 4.3--15.7)                                               570 (22.7, 20.6--24.9)                                                         *3078* (18.3, 17.5--19.1)                                                   1300 (42.2, 39.9--44.5)
  ***At least one non-specific cancer symptom***                            ***2756 (16*.*4*, 15.7--17.1)**                                      ***630 (22*.*9*, *20*.*8--25*.*0)*** [^◊^](#t004fn004){ref-type="table-fn"}    ***3577 (21*.*3*, *20*.*5--22*.*1)***                                       ***1639 (45*.*8*, *42*.*6--49*.*0)*** [^◊^](#t004fn004){ref-type="table-fn"}
  ***At least one red flag symptom***                                       ***1239 (7*.*4*, *6*.*9--7*.*9)***                                   ***278 (22*.*4*, *19*.*4--25*.*5)*** [^◊^](#t004fn004){ref-type="table-fn"}    ***2131 (12*.*7*, *12*.*0--13*.*4)***                                       ***1085 (50*.*9*, *48*.*1--53*.*7)*** [^◊^](#t004fn004){ref-type="table-fn"}
  ***At least one cancer symptom***                                         ***7683 (45*.*8*, *44*.*8--46*.*8)***                                ***2038 (26*.*5*, *25*.*2--27*.*8)*** [^◊^](#t004fn004){ref-type="table-fn"}   ***9810 (58*.*4*, *57*.*4--59*.*4)***                                       ***5836 (59*.*5*, *58*.*5--60*.*5)*** [^◊^](#t004fn004){ref-type="table-fn"}

^¥^ Symptomatic people with information missing about contact with their GP were assumed to have not seen their family doctor

n = number, n/S = number contacting GP/respondents experiencing this symptom, CI = confidence interval

!! = red flag cancer symptom

^◊^ proportion who saw GP for at least one of the symptoms in this group

^‡^ 159/9033 (1.8, 1.4--2.2) in females

^‡‡^ 328/9033 (3.6, 3.1--4.1) in females

More than a third (35.0%) of all respondents reported experiencing at lfeast one symptom possibly indicative of lung cancer in the last year ([Table 4](#pone.0228033.t004){ref-type="table"}). The corresponding figure for upper gastrointestinal cancer symptoms was 29.4%, non-specific cancer symptoms 21.3% and colorectal cancer symptoms 17.3%. Breast cancer symptoms were less common: 3.6% in females and 0.3% in males. Among the 5,880 participants who reported experiencing at least one symptom possibly indicative of lung cancer in the last year, 4,041 (68.7%) had not previously been diagnosed with asthma, chronic bronchitis/COPD or other chest disorder. Similarly, among the 4,929 participants who reported experiencing at least one symptom possibly indicative of upper gastrointestinal tract cancer in the last year, 3,009 (61.0%) had never been diagnosed as having a stomach/digestive disorder.

Characteristics of those experiencing symptoms {#sec019}
----------------------------------------------

Compared with their respective referent group, women, those unable to work because of illness or disability, ex- and current-smokers and those with a history of a specified condition were significantly more likely to report experiencing at least one symptom possibly indicative of the four cancers of interest; in both time periods and after adjusting for other factors ([Table 5](#pone.0228033.t005){ref-type="table"}). On the other hand, those aged 60 to 69 years, those with medium or high social support and those in a household within an income of at least £15,000 were significantly less likely to report at least one symptom possibly indicative of cancer irrespective of what time frame was used. Marital status, education and rurality were not significant variables in the adjusted model. There were generally few statistically significant adjusted differences between subgroups in the chances of experiencing symptoms possibly indicative of the different cancers in the last year ([S2 Table](#pone.0228033.s002){ref-type="supplementary-material"}). Where differences did emerge, the pattern of associations was broadly consistent with that of experiencing any symptom possibly indicative of cancer, i.e. higher reporting among females, those unable to work because of illness, smokers and individuals with a history of one of the specified medical conditions; and less among those aged 60 to 79 years, those with greater social support and those with higher household incomes.

10.1371/journal.pone.0228033.t005

###### Proportion and chance of participants in different subgroups reporting having experienced at least one symptom possibly indicative of cancer in the last month and last year.

![](pone.0228033.t005){#pone.0228033.t005g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                    In the last month   In the last year                                                                              
  --------------------------------------------------------------------------------- ------------------- ------------------------ ----------------------- ------------------- ------------------------ -----------------------
  **Sex** (Male)[^R^](#t005fn004){ref-type="table-fn"}                              44.0 (42.6--45.5)                                                    56.3 (54.9--57.8)                            

  Female                                                                            47.3 (46.0--48.7)   **1.15 (1.06--1.24)**    **1.19 (1.08--1.31)**   60.3 (59.0--61.6)   **1.18 (1.09--1.28)**    **1.19 (1.08--1.32)**

  **Age** (50--59)[^R^](#t005fn004){ref-type="table-fn"}                            44.6 (43.9--46.3)                                                    60.1 (58.4--61.8)                            

  60--69                                                                            43.3 (41.7--44.9)   0.95 (0.86--1.04)        **0.84(0.73--0.96)**    56.0 (54.4--57.6)   **0.85 (0.77--0.93)**    **0.75 (0.66--0.86)**

  70--79                                                                            47.1 (45.0--49.2)   1.10 (0.99--1.23)        0.91 (0.77--1.09)       57.3 (55.2--59.4)   **0.89 (0.80--1.00)**    **0.74 (0.62--0.88)**

  80+                                                                               60.9 (57.2--64.6)   **1.93 (1.63--2.89)**    **1.49 (1.16--1.91)**   68.3 (64.8--71.8)   **1.43 (1.20--1.71)**    1.12 (0.87--1.45)

  **Marital status** (Single)[^R^](#t005fn004){ref-type="table-fn"}                 47.1 (56.0--64.6)                                                    59.8 (56.0--63.6)                            

  Married/living together                                                           43.9 (42.8--45.1)   0.88 (0.75--1.03)        1.07 (0.88--1.30)       56.9 (55.8--58.1)   0.89 (0.75--1.05)        1.05 (0.87--1.28)

  No longer married                                                                 52.9 (50.6--55.2)   **1.26 (1.05--1.51)**    1.16 (0.94--1.43)       64.6 (62.4--66.8)   **1.23 (1.02--1.48)**    1.19 (0.97--1.48)

  **Social support** (Low)[^R^](#t005fn004){ref-type="table-fn"}                    54.8 (50.6--59.1)                                                    66.4 (62.4--70.4)                            

  Medium                                                                            46.7 (45.0--48.4)   **0.72 (0.60--0.87)**    **0.80 (0.65--0.99)**   58.8 (57.1--60.5)   **0.72 (0.60--0.88)**    **0.78 (0.63--0.96)**

  High                                                                              44.6 (43.3--45.9)   **0.66 (0.55--0.79)**    **0.75 (0.61--0.92)**   57.9 (56.6--59.2)   **0.70 (0.58--0.84)**    **0.76 (0.61--0.94)**

  **Education** (No qualifications)[^R^](#t005fn004){ref-type="table-fn"}           51.9 (49.1--54.7)                                                    60.7 (57.9--63.5)                            0.76 (0.61--0.94)

  Secondary school or equivalent                                                    47.6 (45.8--49.4)   **0.84 (0.74--0.96)**    1.00 (0.84--1.17)       59.0 (57.3--60.7)   0.93 (0.81--1.07)\       1.06 (0.90--1.25)
                                                                                                                                                                             1.                       

  College/vocational courses and other                                              49.4 (44.4--54.4)   0.90 (0.72--1.14)        0.95 (0.73--1.25)       62.1 (57.2--67.0)   1.06 (0.84--1.35)        1.05 (0.80--1.38)

  Professional qualification                                                        44.8 (42.8--46.8)   **0.75 (0.66--0.87)**    0.97 (0.81--1.15)       58.8 (56.9--20.7)   0.92 (0.80--1.06)        1.09 (0.91--1.30)

  Degree or postgraduate qualification                                              40.9 (38.9--42.9)   **0.64 (0.56--0.77)**    0.91 (0.76--1.09)       56.0 (54.0--58.0)   **0.82 (0.72--0.95)**    1.04 (0.87--1.25)

  **Employment** (Working full-time)[^R^](#t005fn004){ref-type="table-fn"}          42.3 (40.3--44.4)                                                    57.5 (55.5--59.6)                            

  Working part-time                                                                 42.4 (39.2--45.6)   1.00 (0.86--1.17)        0.89 (0.75--1.07)       56.1 (52.9--59.3)   0.95 (0.81--1.10)        0.88 (0.74--1.05)

  Self-employed                                                                     43.7 (40.1--47.4)   1.06 (0.90--1.26)        1.05 (0.87--1.27)       57.7 (54.1--61.3)   1.01 (0.85--1.20)        1.05 (0.86--1.27)

  Retired                                                                           46.2 (44.8--47.6)   **1.17 (1.06--1.30)**    0.87 (0.74--1.02)       57.7 (56.3--59.1)   1.01 (0.91--1.11)        0.90 (0.77--1.05)

  Unable to work due to illness/disability                                          86.5 (82.2--90.8)   **8.77 (6.02--12.77)**   **5.50 (3.57--8.47)**   91.3 (87.8--94.8)   **7.71 (4.91--12.10)**   **4.72 (2.87--7.76)**

  Others not in paid employment                                                     47.5 (42.0--53.0)   1.23 (0.98--1.56)        0.98 (0.75--1.29)       61.6 (56.3--66.9)   1.18 (0.93--1.51)        1.00 (0.76--1.33)

  **Household income** (\< £15,000)[^R^](#t005fn004){ref-type="table-fn"}           54.7 (52.6--56.9)                                                    64.9 (62.8--67.0)                            

  £15,000--29,999                                                                   45.4 (43.5--47.3)   **0.69 (0.61--0.77)**    **0.82 (0.72--0.94)**   57.0 (55.1--58.9)   **0.72 (0.64--0.81)**    **0.82 (0.71--0.94)**

  £30,000--49,999                                                                   42.5 (40.4--44.6)   **0.61 (0.54--0.69)**    **0.80 (0.68--0.93)**   56.8 (54.7--58.9)   **0.71 (0.63--0.81)**    **0.83 (0.71--0.97)**

  \>£50,000                                                                         38.3 (36.1--40.6)   **0.51 (0.45--0.58)**    **0.68 (0.57--0.81)**   54.6 (52.3--56.9)   **0.65 (0.57--0.74)**    **0.74 (0.62--0.88)**

  **Smoking status** (Never smoked)[^R^](#t005fn004){ref-type="table-fn"}           41.6 (40.3--43.0)                                                    55.0 (53.6--56.4)                            

  Ex-smoker                                                                         50.0 (48.4--51.7)   **1.41 (1.29--1.53)**    **1.29 (1.16--1.42)**   61.8 (60.2--63.4)   **1.32 (1.21--1.45)**    **1.23 (1.12--1.36)**

  Current smoker                                                                    54.2 (50.9--57.6)   **1.67 (1.44--1.93**     **1.54 (1.31--1.83)**   65.5 (62.3--68.7)   **1.55 (1.33--1.80)**    **1.37 (1.15--1.63)**

  **Rural Urban** (Scotland large urban) [^R^](#t005fn004){ref-type="table-fn"}     45.9 (43.6--48.2)                                                    60.9 (58.7--63.1)                            

  Scotland other urban areas                                                        45.5 (42.1--48.9)   0.98 (0.83--1.16)        0.99 (0.82--1.20)       58.6 (55.3--62.0)   0.91 (0.77--1.07)        0.91 (0.75--1.10)

  Scotland accessible small towns                                                   45.6 (40.5--50.7)   0.99 (0.79--1.24)        0.92 (0.71--1.19)       57.8 (52.8--62.8)   0.88 (0.70--1.10)        0.84 (0.65--1.08)

  Scotland remote small towns                                                       45.4 (42-2-48.6)    0.98 (0.84--1.15)        1.03 (0.86--1.24)       57.8 (54.6--61.0)   0.88 (0.75--1.03)        0.94 (0.78--1.13)

  Scotland accessible rural                                                         43.6 (39.5--47.7)   0.91 (0.75--1.10)        0.98 (0.79--1.22)       55.6 (51.5--59.7)   **0.80 (0.66--0.97)**    0.85 (0.68--1.06)

  Scotland remote rural                                                             44.5 (40.5--48.5)   0.95 (0.78--1.14)        0.96 (0.77--1.19)       57.4 (53.4--61.4)   0.87 (0.72--1.04)        0.90 (0.73--1.12)

  England urban with city and town                                                  50.5 (47.9--53.2)   **1.20 (1.04--1.38)**    1.09 (0.92--1.30)       61.9 (59.3--64.5)   1.04 (0.90--1.20)        0.96 (0.81--1.14)

  England urban with significant rural                                              43.7 (41.4--46.0)   0.92 (0.81--1.04)        0.94 (0.81--1.09)       56.5 (54.2--58.8)   **0.83 (0.73--0.95)**    0.87 (0.74--1.01)

  England largely rural                                                             45.9 (43.2--48.6)   1.00 (0.87--1.15)        1.00 (0.85--1.18)       56.6 (53.9--59.3)   **0.83 (0.72--0.96)**    0.85(0.72--1.00)

  **Diagnosis of specified condition** (No)[^R^](#t005fn004){ref-type="table-fn"}   27.0 (25.1--28.9)                                                    40.8 (38.7--42.9)                            

  Yes                                                                               50.8 (49.7--51.9)   **2.80 (2.51--3.12)**    **2.65 (2.35--3.00)**   63.2 (62.1--64.3)   **2.50 (2.26--2.76)**    **2.48 (2.21--2.78)**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI = confidence interval, UOR = unadjusted odds ratio, AOR = adjusted odds ratio

† Number in each subgroup as per [Table 1](#pone.0228033.t001){ref-type="table"}.

\*adjusted odds ratio: adjusted for gender, age, marital status, social support, education, employment, household income, smoking, rurality, ever diagnosis of specified condition, except when the variable itself is being examined.

^R^ = Referent group for odds ratios

Proportion contacting the GP {#sec020}
----------------------------

Overall, 26.5% of respondents experiencing at least one symptom possibly indicative of the four cancers in the last month contacted their GP about at least one symptom, and 59.5% in the previous year ([Table 4](#pone.0228033.t004){ref-type="table"}). The corresponding proportions were smaller among participants experiencing at least one red flag symptom; 22.4% and 50.9% respectively. Contact with the GP varied greatly for individual (including red flag) symptoms; between 15.1% (*hoarseness*) and 50.0% (*persistent vomiting*) for symptoms experienced in the last month and between 28.7% (*hoarseness*) and 77.1% (*lump in breast*) in the last year.

Characteristics of those contacting the GP {#sec021}
------------------------------------------

[Table 6](#pone.0228033.t006){ref-type="table"} shows the association between different characteristics of the respondents and the likelihood of contacting the GP if a symptom possibly indicative of cancer was experienced in the last month or last year. In the adjusted model, compared with their respective referent group, symptomatic women, those aged 80+ years, those unable to work due to illness or disability, ex-smokers and those with a history of a specified condition were more likely to contact their GP about at least one symptom; and people with the highest level of household income less likely to do so. The pattern of associations was the same regardless of the time frame (last month or last year) considered for experiencing symptoms.

10.1371/journal.pone.0228033.t006

###### Proportion and chance of participants in different subgroups experiencing at least one symptom possibly indicative of the four cancers and seeing their GP for at least one such symptom in the last month and last year.

![](pone.0228033.t006){#pone.0228033.t006g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                    In the last month   In the last year                                                                            
  --------------------------------------------------------------------------------- ------------------- ----------------------- ----------------------- ------------------- ----------------------- -----------------------
  Sex (Male)[^R^](#t006fn004){ref-type="table-fn"}                                  25.2 (23.9--26.5)                                                   56.2 (54.8--57.7)                           

  Female                                                                            27.2 (26.0--28.4)   **1.21 (1.07--1.36)**   **1.17 (1.01--1.37)**   62.2 (60.9--63.5)   **1.30 (1.19--1.41)**   **1.29 (1.17--1.43)**

  Age (50--59)[^R^](#t006fn004){ref-type="table-fn"}                                24.9 (23.4--26.4)                                                   55.4 (53.7--57.1)                           

  60--69                                                                            26.2 (24.8--27.6)   1.03 (0.88--1.12)       0.91 (0.74--1.12        59.0 (57.4--60.6)   0.99 (0.89--1.09)       0.90 (0.78--1.03)

  70--79                                                                            27.6 (25.7--29.5)   **1.20 (1.01--1.41)**   1.12 (0.78--1.32        63.8 (61.8--65.8)   **1.15 (1.03--1.29)**   1.00 (0.84--1.20

  80+                                                                               31.0 (27.534.5)-    **1.86 (1.49--2.32)**   **1.54 (1.10--2.16)**   67.0 (63.4--70.6)   **1.69 (1.42--2.00)**   **1.48 (1.15--1.89)**

  **Marital status** (Single)[^R^](#t006fn004){ref-type="table-fn"}                 26.1 (22.7--29.5                                                    57.1 (53.3--60.9)                           

  Married/living together                                                           25.3 (24.3--26.3)   0.89 (0.70--1.14)       1.08 (0.81--1.44)       58.8 (57.7--59.9)   0.97 (0.82--1.15)       1.06 (0.87--1.29)

  No longer married                                                                 30.5 (28.4--32.6)   **1.38 (1.05--1.79)**   1.24 (0.92--1.69)       62.9 (60.7--65.1)   **1.32 (1.10--1.60)**   1.15 (0.92--1.42)

  **Social support** (Low)[^R^](#t006fn004){ref-type="table-fn"}                    23.2 (19.6--26.8)                                                   57.8 (53.6--62.0)                           

  Medium                                                                            25.7 (24.2--27.2)   0.93 (0.71--1.23)       1.08 (0.78--1.48)       58.3 (56.6--60.0)   0.84 (0.69--1.02)       0.90 (0.73--1.12)

  High                                                                              27.3 (26.1--28.5)   0.95 (0.73--1.24)       1.12 (0.82--1.53)       59.9 (58.6--61.2)   0.85 (0.71--1.03)       0.93 (0.75--1.15)

  **Education** (No qualifications)[^R^](#t006fn004){ref-type="table-fn"}           28.3 (25.7--30.9)                                                   64.5 (61.8--67.2)                           

  Secondary school or equivalent                                                    28.1 (26.5--29.7)   0.90 (0.74--1.09)\      0.97 (0.77--1.22        62.0 (60.3--63.7)   0.90 (0.78--1.03)       1.02 (0.86--1.20)
                                                                                                        1.1                                                                                         

  College/vocational courses and other                                              32.2 (27.5--36.9)   1.10 (0.80--1.51)       1.13 (0.78--1.63)       61.2 (56.3--66.1)   0.96 (0.75--1.21)       1.00 (0.75--1.31)

  Professional qualification                                                        25.8 (24.0--27.5)   **0.76 (0.62--0.93)**   0.94 (0.73--1.20)       58.3 (56.4--60.3)   **0.81 (0.70--0.94)**   0.97 (0.81--1.16)

  Degree or postgraduate qualification                                              22.4 (20.7--24.1)   **0.58 (0.47--0.72)**   0.82 (0.63--1.07)       54.4 (52.4--56.4)   **0.68 (0.59--0.79)**   0.88 (0.73--1.07)

  **Employment** (Working full-time)[^R^](#t006fn004){ref-type="table-fn"}          22.5 (20.8--24.2)                                                   53.5 (51.4--55.6)                           

  Working part-time                                                                 27.0 (24.1--29.9)   1.23 (0.96--1.58)       1.04 (0.79--1.38)       58.5 (55.3--61.7)   1.10 (0.94--1.30)       0.98 (0.81--1.18)

  Self-employed                                                                     22.2 (19.1--25.3)   1.02 (0.77--1.36)       0.91 (0.66--1.25)       54.1 (50.4--57.8)   1.02 (0.85--1.23)       0.98 (0.80--1.21)

  Retired                                                                           27.0 (25.8--28.2)   **1.36 (1.15--1.60)**   0.94 (0.73--1.20)       61.4 (60.1--62.7)   **1.24 (1.11--1.38)**   0.93 (0.79--1.10)

  Unable to work due to illness/disability                                          43.4 (37.2--49.6)   **5.73 (4.27--7.70)**   **3.50 (2.47--4.95)**   78.8 (73.7--83.9)   **5.75 (4.29--7.71)**   **3.92 (2.81--5.49)**

  Others not in paid employment                                                     28.2 (23.3--33.1)   **1.47 (1.04--2.09)**   1.27 (0.86--1.90)       63.5 (58.2--68.8)   **1.45 (1.14--1.84)**   1.24 (0.93--1.64)

  **Household income** (\< £15,000)[^R^](#t006fn004){ref-type="table-fn"}           31.0 (29.0--33.0)                                                   64.5 (62.4--66.6)                           

  £15,000--29,999                                                                   26.5 (24.8--28.2)   **0.67 (0.57--0.79)**   0.87 (0.71--1.05)       60.5 (58.6--62.4)   **0.73 (0.65--0.83)**   0.91 (0.79--1.04)

  £30,000--49,999                                                                   24.0 (22.2--25.8)   **0.55 (0.46--0.67)**   0.79 (0.63--1.00)       57.8 (55.7--59.9)   **0.68 (0.60--0.77)**   0.93 (0.79--1.09)

  \>£50,000                                                                         19.9 (18.1--21.8)   **0.40 (0.33--0.50)**   **0.62 (0.47--0.82)**   52.0 (49.7--54.3)   **0.55 (0.48--0.63)**   **0.79 (0.66--0.95)**

  **Smoking status** (Never smoked)[^R^](#t006fn004){ref-type="table-fn"}           25.4 (24.2--26.6)                                                   58.5 (57.2--59.9)                           

  Ex-smoker                                                                         27.9 (26.4--29.4)   **1.37 (1.21--1.56)**   **1.23 (1.06--1.43)**   60.9 (50.3--62.5)   **1.27 (1.16--1.39)**   **1.16 (1.05--1.29)**

  Current smoker                                                                    26.6 23.6--29.6)    **1.43 (1.16--1.76)**   1.21 (0.95--1.54)       57.4 (54.1--60.7)   **1.27 (1.09--1.47)**   1.13 (0.95--1.35)

  **Rural Urban** (Scotland large urban)[^R^](#t006fn004){ref-type="table-fn"}      28.3 (26.3--30.3)                                                   58.2 (56.0--60.4)                           

  Scotland other urban areas                                                        23.6 (20.7--26.5)   0.81 (0.62--1.04)       0.82 (0.61--1.10)       61.0 (57.7--64.3)   1.01 (0.85--1.20)       0.98 (0.81--1.20)

  Scotland accessible small towns                                                   30.5 (25.8--35.2)   1.08 (0.78--1.50)       0.86 (0.58--1.26)       63.0 (58.1--67.9)   1.04 (0.83--1.31)       0.92 (0.71--1.20)

  Scotland remote small towns                                                       25.7 (22.9--28.5)   0.89 (0.69--1.13)       0.86 (0.65--1.13)       58.9 (55.7--62.1)   0.94 (0.79--1.11)       0.92 (0.76--1.12)

  Scotland accessible rural                                                         26.6 (22.9--30.3)   0.88 (0.65--1.18)       0.92 (0.66--1.28)       58.3 (54.2--62.4)   0.87 (0.71--1.07)       0.89 (0.71--1.13)

  Scotland remote rural                                                             28.8 (25.1--32.5)   0.99 (0.75--1.30)       1.01 (0.74--1.39)       58.1 (54.1--62.1)   0.91 (0.75--1.11)       0.92 (0.73--1.15)

  England urban with city and town                                                  28.5 (26.1--30.9)   1.12 (0.92--1.38)       0.95 (0.75--1.21)       61.7 (59.1--64.3)   1.13 (0.97--1.30)       1.00 (0.84--1.19)

  England urban with significant rural                                              24.6 (22.6--26.6)   0.81 (0.66--0.99)       0.79 (0.63--1.00)       59.7 (57.5--61.9)   0.92 (0.81--1.06)       0.89 (0.76--1.04)

  England largely rural                                                             24.7 (22.4--27.0)   0.86 (0.69--1.06)       0.82 (0.64--1.05)       58.2 (55.6--60.9)   0.89 (0.77--1.04)       0.85 (0.72--1.01)

  **Diagnosis of specified condition** (No)[^R^](#t006fn004){ref-type="table-fn"}   17.0 (15.4--18.6)                                                   43.0 (40.9--45.2)                           

  Yes                                                                               27.9 (26.9--28.9)   **3.44 (2.77--4.27)**   **2.97 (2.32--3.79)**   62.3 (61.2--63.4)   **3.05 (2.70--3.45)**   **2.80 (2.44--3.21)**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI = confidence interval, UOR = unadjusted odds ratio, AOR = adjusted odds ratio

† Number in each subgroup as per [Table 1](#pone.0228033.t001){ref-type="table"}.

\*adjusted odds ratio: adjusted for gender, age, marital status, social support, education, employment, household income, smoking, rurality, ever diagnosis of specified condition, except when the variable itself is being examined.

^R^ = Referent group for odds ratios

Discussion {#sec022}
==========

Main findings {#sec023}
-------------

Symptoms possibly indicative of cancer were common in the adults surveyed in our study, with nearly half experiencing at least one such symptom in the last month and nearly three-fifths in the last year. Many people experienced multiple symptoms. The prevalence of individual symptoms varied widely, with red flag symptoms at the lower end of the range. The prevalence of symptoms varied within different population subgroups. More than three quarters of respondents experiencing at least one red flag symptom in the last month did not reported it to their GP, and nearly half of those experiencing such symptoms in the last year. There were important variations in the level of GP help-seeking by symptom type and the characteristics of person experiencing them.

Strengths and limitations {#sec024}
-------------------------

The USEFUL study is the largest investigation so far in the UK of the prevalence and GP help-seeking responses to symptoms possibly indicative of cancer in a community setting. Its large size meant that we had good precision for common symptoms. The questionnaire underwent detailed refinement during both the development phase when experts and lay members reviewed early drafts and the pilot phase which resulted in some changes to make the questionnaire easier to follow. A key consideration when discussing early drafts was whether our symptom descriptors accorded with lay understanding. The symptom components of the questionnaire were based on a questionnaire used in a previous study, which had been found to collect appropriate data \[[@pone.0228033.ref017], [@pone.0228033.ref018]\]. Questions about the specific concepts of illness perceptions and cancer awareness were taken from validated questionnaires (Brief Illness Perception Questionnaire \[[@pone.0228033.ref029]\] and Cancer Awareness Measure \[[@pone.0228033.ref016]\]). We looked at symptom experience over the past month (the main focus) and past year. The patterns of associations were the same regardless of the time frame used. It was useful to include both timeframes to ensure our findings were comparable to previous research in other countries \[[@pone.0228033.ref013]\].

Masking symptoms were included in the questionnaire, and the explicit mention of cancer avoided, to limit potential anxiety and minimise the biasing of responses. Even so, some recipients may have become aware of our interest in cancer, having seen a description of the study on a publically accessible website, such as that of Cancer Research UK which stated that the study was looking at cancer. Three recipients of the invitation to participate contacted us to clarify the study's purpose. Although some participants reported a history of cancer when completing the questionnaire. We have no information about cancer screening within the study sample. We found that the inclusion of people with a history of cancer did not materially affect our prevalence results. Some of the reported symptoms are likely to have arisen from other chronic conditions. Nevertheless, most cancer awareness campaigns are targeted at the total population regardless of previous or current medical history, so understanding the prevalence and pattern of cancer-related symptoms, and associated help-seeking behaviour, in the total population is essential. Previous studies investigating GP help-seeking have often focused on individuals with cancer, retrospectively examining their symptom experiences prior to diagnosis \[[@pone.0228033.ref005]--[@pone.0228033.ref007], [@pone.0228033.ref030]--[@pone.0228033.ref034]\]. Such studies are limited by variable patient recall \[[@pone.0228033.ref035]\] and possible changes in symptom interpretation post diagnosis \[[@pone.0228033.ref036]\]. Our study participants were of an age (50+ years) when the incidence of cancer rises sharply, and when many cancer initiatives, such as screening, cancer awareness campaigns or clinical guidance of prompt investigation for particular symptoms begins \[[@pone.0228033.ref037], [@pone.0228033.ref038]\]. Thus, our results may match reality more closely than those of studies involving a different age group or asking about anticipated delays for hypothetical scenarios \[[@pone.0228033.ref012], [@pone.0228033.ref039], [@pone.0228033.ref040]\].

We were able to consider a large number of factors in the analyses that may be related to the reporting of symptoms possibly indicative of cancer. Some consistent associations were observed, both overall and for symptoms associated with different types of cancer. The cross-sectional nature of the study, however, means that we are unable to determine whether the observed associations were causal. Furthermore, as with any observational study, residual confounding from factors (such as lifestyle) not included in the model may have occurred. This said, our observations should be informative for the targeting of future cancer symptom awareness campaigns and interventions throughout the UK.

We did not have information about how many practices approached by the research networks declined to participate, or about the characteristics of participating practices compared to non-participating practices. In addition, we have no information about the number of, and reasons for, exclusions made by the participating practices when screening the lists of potential invitees. We do not know therefore how generalizable our results are to the wider UK population.

The sampling of patients registered with a GP is a method routinely used in the UK for sampling the general population since most people are registered with a GP so that they can obtain healthcare. Non-registered individuals who were excluded from our study may have a different experience of symptoms possibly indicative of cancer than participants in our study, and probably different patterns of response to these symptoms. A key consideration when interpreting our findings is the low response rate; a common problem with recent epidemiological research \[[@pone.0228033.ref004], [@pone.0228033.ref015], [@pone.0228033.ref017], [@pone.0228033.ref018], [@pone.0228033.ref041], [@pone.0228033.ref042]\]. We tried to mitigate against a low response rate by using a number of recommended approaches \[[@pone.0228033.ref043]\], including inviting participation using personalised letters on general practice-headed notepaper, offering both on-line and paper questionnaires and sending two reminders. We did not have ethics approval or resources to increase participation further, such as by using a telemarketing company to approach non-responders or holding a lottery for respondents \[[@pone.0228033.ref014]\]. The primary concern with low response rates is its potential to introduce bias. There was evidence of differential response by gender, age, rurality and deprivation. It is difficult to assess the overall impact of this on our findings, although there may have been some underestimation of symptom prevalence since those on lower incomes (less likely to respond) appeared more likely to report symptoms possible indicative of cancer.

As with all other investigations of symptoms, our study was based on self-reported information. Deliberately, we did not define or explain symptom descriptors such as 'persistent' or 'unexplained'. It is likely that these descriptors have different meanings for different people. In a separate exercise we have conducted qualitative interviews with a number of participants to examine their perceptions of the term 'persistence'. These findings will be published in a separate paper. Importantly, our study shows how many people perceived themselves to have such symptoms, and how they responded. We have found that participant self-report of help-seeking for symptoms possibly indicative of cancer is reasonably accurate \[[@pone.0228033.ref044]\]. Individuals may have differed in their understanding of what was meant by the symptoms listed, although our development work involved members of the general public in an attempt to mitigate against this. Furthermore, many people had a previous diagnosis of a number of medical conditions, reflecting the age profile of our sample. We do not know how many people had active symptomatic disease, particularly chronic disease, which may affect awareness and response to different symptoms. Where we were able to assess this (i.e. for symptoms possibly indicative of lung or upper gastrointestinal cancer) we found that most symptoms occurred in participants without a previous relevant diagnosis; suggesting that our findings were not simply due to a high proportion of participants with historic diagnoses which had been symptomatic for some time. Although subjective, symptoms are powerful drivers of healthcare service use, so understanding how people experience and react to them remains crucial.

Space constraints prevent us from presenting in-depth patterns of, and different influences on, help-seeking responses to experienced symptoms. Subsequent papers will provide this information. Nevertheless, the top-level results presented here show important variations within the general population in GP help-seeking behaviour, highlighting the need for research in this area.

Other studies {#sec025}
-------------

Few studies have assessed a range of symptoms possibly indicative of cancer from a community perspective. Furthermore, comparison between studies can be difficult because of differences in the range of symptoms assessed, descriptors used and the age of participants. For example, only six of the 44 symptoms included in the Danish Symptom Cohort study \[[@pone.0228033.ref014]\] used the same wording as our study; with another four using broadly similar wording ([Table 7](#pone.0228033.t007){ref-type="table"}). The proportion of people in the Danish study experiencing these symptoms in the preceding month was higher (albeit sometimes only marginally) for eight of the ten symptoms, than in our study. Some of the differences may be attributable to the inclusion of younger participants in the Danish study; we found in a previous UK study \[[@pone.0228033.ref018]\] a higher prevalence of symptoms among younger people. The Danish study also found that more people contacted their GP for seven of the ten symptoms. Indeed the level of contact with a GP for at least one symptom (37%) was high in the Danish study. Another study conducted in one region of Denmark (Funen), of adults aged 20+ years, reported a higher proportion of people experiencing having a *lump in the breast* during the preceding 12 months (3.3%), a similar proportion with *blood in stool* (5.7%) and a lower proportion with *cough longer than six weeks* (6.5%), than in our study. These differences highlight the need for country specific information about the prevalence of symptoms experienced in the community, and associated help-seeking behaviour. Our prevalence and contact with GP findings, obtained from an older population responding to questions focused in symptoms possibly indicative of cancer and which included terms such as persistent, are most pertinent to planners of UK-based cancer awareness campaigns.

10.1371/journal.pone.0228033.t007

###### Comparison of the proportion of people reporting different symptoms and proportion seeking GP help in the last month, between our study and the Danish Symptom Cohort \[[@pone.0228033.ref014]\].

![](pone.0228033.t007){#pone.0228033.t007g}

                                                                  Our study   Danish Study          
  --------------------------------------------------------------- ----------- -------------- ------ ------
  Same wording:                                                   \%          \%             \%     \%
  Difficulty swallowing                                           3.4         18.0           3.5    34.9
  Hoarseness                                                      4.6         15.1           7.7    18.7
  Coughing up blood                                               0.2         27.8           0.1    47.5
  Shortness of breath                                             11.9        28.3           8.0    49.7
  Blood in stool or rectal bleeding                               2.9         19.3           4.6    33.7
  Loss of appetite                                                2.8         20.9           6.3    19.4
  Slightly different wording- our study / Danish study wording:                                     
  Stomach or abdominal pain / abdominal pain                      9.9         25.7           19.6   27.8
  Persistent vomiting / repeated vomiting                         0.2         50.0           1.3    33.6
  Vomiting up blood / blood in vomit                              0.0         0              0.1    37.0
  Unexplained weight loss / weight loss                           0.9         39.9           3.0    25.1

A postal questionnaire-based study 3,756 individuals aged 50+ years without cancer and recruited from seven general practices in London, South East and North West England asked about the occurrence of 10 cancer red flag symptoms in the last three months. \[[@pone.0228033.ref015]\]. Like our study, the prevalence of symptoms was high: 46% of participants reported at least one red flag symptom, with individual symptom prevalence ranging between 2.9% (*unexplained bleeding*) and 16.9% (*cough or hoarseness*). Similar to our study, there was a wide variation in the proportion of symptoms resulting in GP help-seeking: overall 67% of all symptoms were presented, and individually between 53.5% (*cough or hoarseness*) and 72.0% (*unexplained lump*) of symptoms.

The Funen study also looked at factors associated with the reporting of at least one cancer red flag symptom \[[@pone.0228033.ref045]\]. It found that women, individuals not in the workforce (including because of disability), and those with a cancer diagnosis were more likely to report at least one red flag symptom; with older participants and those living with a partner less likely. Apart from age, these associations are consistent with our findings.

Implications {#sec026}
------------

Cancer awareness campaigns can increase the proportion of symptomatic individuals seeking help. For example, a national eight week campaign in England in 2012, focused on persistent or prolonged cough as a prompt to seek help to avoid lung cancer \[[@pone.0228033.ref046]\]. It resulted in a 3% increase in the public's awareness of the potential importance of this symptom (from 12% to 15%), and led to a 67% increase during the campaign in patients of all ages visiting their GP with a cough- equivalent to six extra consultations per practice per week.

Our results highlight the potential implications of such campaigns for healthcare services, particularly general practice. In our study, 13% of respondents had a persistent cough in the previous year, half of whom saw their GP. If those not currently seeing their GP responded positively to a cancer awareness campaign, 6.5% (1 in 15) of all adults in the UK aged 50+ might contact their GP for help. Better understanding of how and why people with particular characteristics respond to symptoms experienced, should enable the tailoring of messages within cancer awareness campaigns for greater effectiveness.

Conclusion {#sec027}
==========

Symptoms possibly indicative of cancer are common among adults aged 50+ years in the UK, although they are not evenly distributed. Help- seeking responses to different symptoms also vary. Our results suggest important opportunities to provide more nuanced messaging and targeting of symptom-based cancer awareness campaigns.

Supporting information {#sec028}
======================

###### Response rates in Scotland and England.

(DOCX)

###### 

Click here for additional data file.

###### Proportion and chance of participants in different subgroups having experienced at least one symptom possibly indicative of different cancers in the last year.

(DOCX)

###### 

Click here for additional data file.

###### Questionnaire content.

(DOCX)

###### 

Click here for additional data file.
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Reviewer \#1: This is a well written manuscript with an interesting research question with many implications for improving cancer awareness research. However, there are some concerns that need to be addressed.

1\. There is a mention of focus on red flag symptoms in the introduction but there were not enough details describing what these red flag symptoms were and how they were determined.

In addition to identifying the red flag symptoms in table 1 we have listed them in the methods section and defined them. We have also indicated that those selected were based on those highlighted in cancer referral guidelines..

2\. The study was described as a large community based sample, however more details about the study sampling method should be described to fully understand the sampling population. How did the practices who participated differ from those who did not participate? Moreover, while the reasons for exclusions and number of exclusions were not collected, this is critical for the generalizability of the study and should be addressed further in the discussion.

This is an important issue which we have expanded upon in the discussion: 'We did not have information about how many practices approached by the research networks declined to participate, or about the characteristics of participating practices compared to non-participating practices. In addition, we have no information about the number of, and reasons for, exclusions made by the participating practices when screening the lists of potential invitees. We do not know therefore how generalizable our results are to the wider UK population'.

3\. While the questionnaire was a useful instrument for measuring the symptoms in this study, is there any information available about the validity and reliability measures? How well does the questionnaire measure what it is supposed to measure? What is the construct validity of the questionnaire?

We have added some additional text about this in the opening paragraph of the strengths and limitations section of the discussion. 'The questionnaire underwent detailed refinement during both the development phase when experts and lay members reviewed early drafts and the pilot phase which resulted in some changes to make the questionnaire easier to follow. A key consideration when discussing early drafts was whether our symptom descriptors accorded with lay understanding. The symptom components of the questionnaire were based on a questionnaire used in a previous study which had been found to collect appropriate data \[17, 18\]. Questions about the specific concepts of illness perceptions and cancer awareness were taken from validated questionnaires (Brief Illness Perception Questionnaire \[29\] and Cancer Awareness Measure \[16\]).

4\. How were the variables in the models chosen for the analyses? There is no description of how selection of variables were conducted or how they were entered into the models. I

We have added a clarification to the methods section that the variables included in the model were chosen a priori on the basis of previous research. We have also clarified that all of the variables were entered simultaneously into the model.

5\. It would be interesting to understand how the participants over the three mailings might have differed in any of the symptoms. Whether those who needed more reminding differed in any of the characteristics that may be related to the symptoms.

We agree this is an interesting issue and we had intended looking at it in a subsequent methodological paper. Given the already large amount of information contained in our paper we do not think it is appropriate to include this analysis here.

6\. It was reported that masking symptoms was critical to minimize any biases in the responses, however some participants contacted the study to clarify the purpose. It would be important to know how many participants contacted the study and if it is of concern.

We have altered this section slightly to clarify the situation- we do not know exactly how many of the questionnaire recipients thought our questionnaire was about cancer, although we do know that three contacted us specifically to ask about this. The overall number of people who thought this was about cancer is likely to be small.

7\. While this research question is interesting, it is still puzzling to understand how some of these symptoms for cancer may be differentiated from a lot of other chronic diseases. Also, it may be important to have information about how many participants actually receive any cancer screening in this population

We have added some clarification to the discussion paaraghp starting 'Masking symptoms..' \[original text in blue\] ... Although some participants reported a history of cancer when completing the questionnaire. We have no information about cancer screening within the study sample. We found that the inclusion of people with a history of cancer did not is unlikely to have materially affected our prevalence results. Some of the reported symptoms are likely to arisen other chronic diseases. Furthermore Nevertheless, most cancer awareness campaigns are targeted at the total population regardless of previous or current medical history, so understanding the prevalence and pattern of cancer-related symptoms, and associated help-seeking behaviour, in the total population is essential...\...

Reviewer \#2: Thank you for the opportunity to review this interesting paper from a very knowledgeable author group.

The study aims to improve the understanding of the prevalence, patterning and response to symptoms associated with breast, colorectal, lung and upper gastrointestinal cancer in older adults living in the UK general population.

The study adds information to the field, although studies of symptom experiences and healthcare seeking behavior in the population in Western Countries, among others UK and Denmark, have already been published in recent years.

The authors argue that enhanced understanding of the prevalence of symptoms possibly indicative of cancer in different population subgroups, and associated help-seeking behaviour, will help to target cancer awareness campaigns more effectively.

The paper is well written overall and to presents novel data of the UK general population.

The author group describe that their results suggest important opportunities to provide more nuanced messaging and targeting of symptom-based cancer awareness campaigns. After having read the paper, I am though left with the impression that they do not really address this in the discussion. The paper is in that way more descriptive than analytic.

A few methodological issues are raised below:

Related to the questionnaire development: How was 'persistent' explained for the respondents? Did the authors make any attempts to qualify how respondents interpreted the questions, and probably also how the interpretations differed among respondents?

In line with this question: How was unexplained interpreted?

Persistent symptoms: We did not explain or define persistent in the questionnaire. This was intentional.

My PhD revealed considerable variation in what people mean by 'persistent'. I therefore explored this further in the USEFUL interviews. So we will be able to shed some light on this in the future. We can't comment on how it was interpreted from the questionnaire, but this is one the strengths of the mixed methods approach, which might be worth highlighting.

Nor can we comment on how participants interpreted 'unexplained'. Interesting though -- perhaps one to explore in future studies?

We have clarified this issue in the discussion paragraph starting 'As with all other investigations.... As with all other investigations of symptoms, our study was based on self-reported information. Deliberately, we did not define or explain symptom descriptors such as 'persistent' or 'unexplained'. It is likely that these descriptors have different meanings for different people. In a separate exercise we have conducted qualitative interviews with a number of participants to examine their perceptions of the term 'persistence'. These findings will be published in a separate paper. Importantly, our study shows how many people perceived themselves to have such symptoms, and how they responded. We have found that participant self-report of help-seeking for symptoms possibly indicative of cancer is reasonably accurate.....

I wonder why the author group choose to ask about symptom experiences in the last year. In the literature it is argued that recall bias is a huge problem when asking for more than 6-8 weeks back. Moreover, recall about help-seeking in the past year might be problematic. Some considerations on this issue should be added to the paper

We have replaced the previous text with the following: We looked at symptom experience over the past month (the main focus) and past year. The patterns of associations were the same regardless of the time frame used. It was useful to include both timeframes to ensure our findings were comparable to previous research in other countries \[13\].

We have also changed the abstract to give one month prevalence figures for the least and most common symptoms, reflecting our focus on one month data.
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